program overview, friday, december 6, 2019

3

PROGRAM OVERVIEW, FRIDAY, DECEMBER 6, 2019

A 09:00 – 10:30 HALL B

Opening session

(talk 1 and 2: 20 minutes + 5 minutes discussion, talk 3 and 4: 14 minutes + 4 minutes discussion)

Chairs: Annemie Schols (The Netherlands) John Morley (USA)

09:00 – 09:04WelcomeStefan Anker (Germany)

1. 09:04 – 09:24“Prometheus” basic science key note lectureProteolysis in muscle wasting: past, present and futureDidier Attaix (France)

2. 09:29 – 09:49“Hippocrates” clinical science key note lectureWhy skeletal muscle matters in chronic heart failureAndrew Coats (UK)

3. 09:54 – 10:08Recent facts & figures: cachexia & SCWDStefan Anker (Germany)

4. 10:12 – 10:26Recent facts & figures: sarcopenia & frailty (the JCSM lecture)Stephan von Haehling (Germany)

10:30 – 11:00 Coffee Break

4


B 11:00 – 13:00 HALL B

Novel targets parade

(talk 1: 12 minutes + 4 minutes discussion, talk 2 to 8: 10 minutes + 3 minutes discussion)

Chairs: Samuel Breit (Australia) Hans Degens (UK) Xiaonan Wang (USA)

1. 11:00 – 11:12State of the art lecture: therapeutic interventions targeting mitochondria – rationale & clinical resultsMichelangelo Mancuso (Italy)

2. 11:16 – 11:26Novel tumor-derived mediators of cachexiaMauricio Berriel Diaz (Germany)

3. 11.29 – 11:39Metastasis and cancer cachexiaSwarnali Acharyya (USA)

4. 11:42 – 11:52Epi-genomics landscapes in cancer cachexiaSøren Fisker-Schmidt (Germany)

5. 11:55 – 12:05Mechanism of p300 activation and mediation of muscle wasting in cancer cachexiaYi-Ping Li (USA)

6. 12:08 – 12:18Targeting the ubiquitin-proteasome system to counteract cancer cachexia – update 2019Volker Adams (Germany)

7. 12:21 – 12:31Activating Mas receptor to reduce cachexiaGordon Lynch (Australia)

8. 12:34 – 12:44Intervention strategies targeting Critical Illness Myopathy (CIM) and Ventilator Induced Diaphragm Dysfunction (VIDD)Lars Larsson (Sweden)

9. 12:47 – 12:57L-ornithine L-aspartate for the treatment of sarcopenia in liver cirrhosisRoger Butterworth (Canada)

C 11:00 – 13:00 HALL A

Bone, muscle and appetite in cachexia and sarcopenia

(each talk: 8 minutes + 3 minutes discussion)

Chairs: Paola Costelli (Italy) Josep Argiles (Spain)

1. 11:00 – 11:08 Musculoskeletal complications of cancer and its treatmentsAndrea Bonetto (USA)

2. 11:11 – 11:19 Muscle-bone crosstalk – results from the experimental studiesRobert Kob (Germany)

3. 11:22 – 11:30Bone-muscle crosstalk in bone metastatic cancerDavid Waning (USA)

4: 11:33 – 11:41Role of muscle and bone factors in energetics and metabolismGustavo Duque (Australia)

5. 11:44 – 11:52The role of microRNA in osteosarcopeniaHanna Taipaleenmäki (Germany)

6. 11:55 – 12:03Does testosterone play a key role in osteosarcopenia?Giuseppe Rosano (UK)

7. 12:06 – 12:14Low muscle mass and strength as a risk factor for fracture – clinical studiesJürgen Bauer (Germany)

8. 12:17 – 12:25Impact of the fracture on muscle strength and physical performancePawel Szulc (France)

9. 12:28 – 12:36Receptor-modified approach on anorexia-cachexia syndrome with an emphasis of ghrelin-neuropeptide Y-orexin hunger systemYasuhito Uezono (Japan)

12:39 – 13:00Panel discussion

5


13:15–14:15 HALL B

Lunch Session of the Journal of Cachexia, Sarcopenia and Muscle (JCSM)

Chairs: Stefan Anker (Germany) Andrew Coats (UK)

JCSM and its daughter journalsStephan von Haehling (Germany)

Open Access publishing / Institutional publication funds / the Wiley DEAL for GermanyJenny Delasalle (Germany)

Panel discussion

D 14:30 – 16:00 HALL B

Cachexia, sarcopenia and frailty in acute illness: clinical discussion


Chairs: Bette Caan (USA) Stephan von Haehling (Germany)

1. 14:30 – 14:44Assessing muscle and fat mass using imaging and biomarker tests in the critical ill: practical approachEmanuele Marzetti (Italy)

2. 14:48 – 15:02Critical-illness induced wasting of muscular fat tissueWerner Z’Graggen (Switzerland)

3. 15:06 – 15:20Critical-illness acquired weakness (ICU-AW)Tobias Wollersheim (Germany)

4. 15:24 – 15:38Outlook: additional critical illness induced neuromuscular dysfunctionsJoerg Schefold (Switzerland)

5. 15:42 – 15:56Nutritional interventions in the ICU: an overviewArthur van Zanten (The Netherlands)

E 14:30 – 16:00 HALL A

Myogenesis for cachexia / sarcopenia


Chairs: Denis Guttridge (USA) James Carson (USA)

1. 14:30 – 14:44Mesoangioblast-driven muscle regeneration in agingMaurilio Sampaolesi (Belgium)

2. 14:48 – 15:02Twist1, myogenesis and cancer cachexiaAzeddine Atfi (USA)

3. 15:06 – 15:20The S100B/RAGE pathway in myogenesis impairmentGuglielmo Sorci (Italy)

4. 15:24 – 15:38Myoparr, a novel mediator of muscle wastingKunihiro Tsuchida (Japan)

5. 15:42 – 15:56The relevance of studying old vs . young animalsConnie Jackaman (Australia)

16:00 – 17:00 Coffee break

6


16:05 – 16:55 POSTER AREA

Poster Viewing 1

(each presentation: 2 minutes + 2 minutes discussion)

Poster session 1 .1 Cachexia – mechanisms, animal models I (posters 1-11 to 1-18) Chairs: Gordon Lynch, Jochen Springer

Poster session 1 .2 Cancer cachexia III (posters 3-24 to 3-29) Chairs: Andrea Bonetto, Paola Costelli

Poster session 1 .3 Diagnosis of cachexia (posters 4-01 to 4-13) Chairs: Vickie Baracos, Florian Strasser

Poster session 1 .4 Diagnosis of sarcopenia I (posters 5-01 to 5-12) Chairs: Robert Mak, Angela Sanford

Poster session 1 .5 Muscle wasting & sarcopenia I (posters 6-01 to 6-11) Chairs: Scott Brakenridge, Joseph Gordon

Poster session 1 .6 Therapeutic Development I (posters 9-01 to 9-10) Chairs: Jose Garcia, Jennifer Le-Rademacher

16:10 – 16:50 HALL A

Rapid Fire Abstracts Session 1


Chairs: Swarnali Acharyya (USA) Stephen Harridge (UK)

16:10 – 16:1318F-FDG PET imaging in preclinical tumour-bearing mouse models of cachexia suggests that Fn14 plays a role in glycolytic changes in the tumour occurring during cancer cachexia (1-05) Ingrid Burvenich (Australia)

16:15 – 16:18 Serological, morphological and molecular markers of denervation and NMJ degeneration underlie muscle wasting in human cancer cachexia (1-08) Sandra Zampieri (Italy)

16:20 – 16:23 Exploring the contribution of the liver to cancer cachexia development (2-05)Eveline Molocea (Germany)

16:25 – 16:28 Interleukin-6 controls microRNA-regulated networks in skeletal muscle cells (2-09)Robson Carvalho (Brazil)

16:30 – 16:33 ZIP14 as a mediator of cachexia in metastatic cancers (2-14)Anup Biswas (USA)

16:35 – 16:38 Inflammatory pathways involved in the gut-brain axis in cachexia (3-09)Xiaolin Li (The Netherlands)

16:40 – 16:43 Lipocalin 2 is a driver of sickness response during pancreatic cancer cachexia (3-23)Brennan Olson (USA)

mdiek

Durchstreichen

7


F 17:00 – 18:30 HALL B

Cachexia in chronic illness: update 2019


Chairs: Kamyar Kalantar-Zadeh (USA) Oliver Bathe (Canada)

1. 17:00 – 17:14Cachexia in chronic obstructive pulmonary diseaseAnnemie Schols (The Netherlands)

2. 17:18 – 17:32Cachexia and protein-energy wasting liver disease Srinivasan Dasarathy (USA)

3. 17:36 – 17:50Diagnosis, treatment and prevention of cardiac cachexia in heart failure Stephan von Haehling (Germany)

4. 17:54 – 18:08Liver cachexiaMatthias Plauth (Germany)

5. 18:12 – 18:26Anorexia and cachexiaMaurizio Muscaritoli (Italy)

G 17:00 – 18:30 HALL A

Muscle stem cells and regeneration in sarcopenia and cachexia


Chairs: David Glass (USA) Volker Adams (Germany)

1. 17:00 – 17:14Regulation of muscle stem cells and regeneration during aging in humansAbigail Mackey (Denmark)

2. 17:18 – 17:32Cross-talk between muscle stem cells, inflammation and fibrosis during muscle regeneration in agingAlessandra Sacco (USA)

3. 17:36 – 17:50Therapeutic interventions targeting cellular communication in the aged stem cell nicheJerome Feige (Switzerland)

4. 17:54 – 18:08Myogenic commitment in cancer cachexiaDenis Guttridge (USA)

5. 18:12 – 18:26Cell therapy of muscle injuries: basic principles and new insights in mechanismsSven Geißler (Germany)

18:30 – 20:00 Wine & Cheese Welcome Reception in Poster Area

8

PROGRAM OVERVIEW, SATURDAY, DECEMBER 7, 2019

8:00 – 8:45 HALL B

Breakfast Seminar

Biomarkers in cachexia

Chairs: Stefan Anker (Germany) Giuseppe Rosano (UK) Andrew Coats (UK)

Biomarkers for risk assessment in cachexiaStephan von Haehling (Germany)

Biomarkers for muscle mass assessment in sarcopenia & cachexiaEmanuele Marzetti (Italy)

Cancer cachexia as cardiovascular disease: evidence from biomarker researchMarkus Anker (Germany)

Supported by educational grant from Thermofisher

8:00 – 8:45 HALL II

Ken Fearon Career Café – Meet the Mentor

Coordinated by: Mitja Lainscak (Slovenia)

8:00 – 8:45 HALL A

Statistical Seminar

An introduction to time-to-event (survival) analysis

Coordinated by: Jennifer Le-Rademacher (USA) Ruta Brazauskas (USA)

Time-to-event outcomes such as time from treatment to disease recurrence or time from diagnosis to death are common endpoints in biomedical research. These outcomes require that the study subjects be followed over time. In practice, it is not possible to follow all subjects until they experience the events of interest. The event times for subjects who are lost to follow-up before experiencing the events are not observed. These patients are censored at the time of their last follow-up. Time-to-event analysis (commonly called survival analysis) methods are needed in studies with time-to-event outcome to account for censoring. Due to the complexity of time-to-event methods, knowledge of the method assumptions and basic principles is important. Great care is needed when applying them in practice or interpreting published studies. In this seminar, we will

− Introduce basic concepts of time-to-event data and explain the difference between various types of survival data including competing risks data

− Introduce common analysis methods including the Kaplan-Meier estimator, the Cox proportional hazards model, the cumulative incidence function, and the Fine-Gray model; and

− Provide practical guidance for analyzing time-to-event data.

9


H 9:00 – 10:30 HALL B

Symptoms of patients with cachexia and their therapy


Chairs: Aminah Jatoi (USA) Rainer Wirth (Germany)

1. 09:00 – 09:14Swallowing problemsHidetaka Wakabayashi (Japan)

2. 09:18 – 09:32PainFlorian Strasser (Switzerland)

3. 09:36 – 09:50DepressionJoanne Reid (UK)

4. 09:54 – 10:08Muscle weakness and fatigue: how to assess objectivityRichard Dunne (USA)

5. 10:12 – 10:26Shortness of breathMarkus Anker (Germany)

I 9:00 – 10:30 HALL A

Mitochondria: a nexus for muscle wasting and impaired metabolism


Chairs: Marco Sandri (Italy) Jochen Springer (Germany)

1. 09:00 – 09:14Mitochondrial dynamics in the regulation of muscle mass Antonio Zorzano (Spain)

2. 09:18 – 09:32Oxidative stress impact on muscle mass and function Maria Carmen Gomez-Cabrera (Spain)

3. 09:36 – 09:50Feeding mitochondria to counteract cachexia Klaske van Norren (The Netherlands)

4. 09:54 – 10:08Exercise and oxidative metabolism in muscle wasting James Carson (USA)

5. 10:12 – 10:26Nix induced mitochondrial fission, mitophagy, and myocyte insulin resistance are abrogated by PKA phosphorylationJoseph Gordon (Canada)

10:30 – 11:30 Coffee Break


Poster Viewing 2


Poster session 2 .1 Cachexia – mechanisms, animal models II (posters 1-01 to 1-10) Chairs: Gordon Lynch, Jochen Springer

Poster session 2 .2 Cachexia – mechanisms, basic (posters 2-01 to 2-14) Chairs: Yi-Ping Li, Fabio Penna

Poster session 2 .3 Cancer cachexia I (posters 3-01 to 3-12) Chairs: Jeffrey Crawford, Stephan von Haehling

Poster session 2 .4 Muscle wasting & sarcopenia II (posters 6-12 to 6-22) Chairs: Srinivasan Dasarathy, Wolfram Doehner

Poster session 2 .5 Nutrition and appetite II (posters 7-13 to 7-24) Chairs: Akio Inui, Arthur van Zanten

Poster session 2 .6 Physical activity & training I (posters 8-01 to 8-11) Chairs: Volker Adams, Mikel Izquidero

10


10:40 – 11:20 HALL A


(each presentation: 3 minutes + 2 minute discussion)

Chairs: Matthias Plauth (Germany) Toshihiko Yada (Japan)

10:40 – 10:43Dysregulation of small non-coding RNAs in the skeletal muscle and in plasma-derived microvesicles during experimental cancer cachexia (4-05)Marc Beltra Bach (Italy)

10:45 – 10:48NMJ failure in aged C57BL/6J mice: defining the timeline and investigating potential therapeutics (5-04)David Arnold (USA)

10:50 – 10:53GDF-15 circulating levels in cancer patients with anorexia and sarcopenia (5-19)Alessio Molfino (Italy)

10:55 – 10:58Low-magnitude, high-frequency vibration treatment attenuates age-related neuromuscular junction degeneration (5-24)Simon Chow (China)

11:00 – 11:03Biostatistical approaches for drug repositioning: NUDT3 & KLF5 for lean mass & HLA-DQB1-AS1 for hand grip skeletal muscles traits and their associated SNPs as candidate targets (6-01)Abhishek Narain Singh (Finland)

11:05 – 11:08Spsb1 is involved in inflammation-induced muscle atrophy (6-02)Yi Li (Germany)

11:10 – 11:13Muscle wasting in cancer involves suppression of ribosomal production and increased expression of the ribophagy receptor NUFIP1 (6-06)Gustavo Nader (USA)

11:15 – 11:18Skeletal muscle mTORC1 regulates neuromuscular junction stability (6-07)Bert Blaauw (Italy)

11


J 11:30 – 13:00 HALL B

Sarcopenia and frailty in chronic illness


Chairs: Francesco Landi (Italy) John Morley (USA)

1. 11:30 – 11:44Sarcopenia in chronic kidney disease and its therapyKamyar Kalantar-Zadeh (USA)

2. 11:48 – 12:02Sarcopenia in COPD and its therapyRamon Langen (The Netherlands)

3. 12:06 – 12:20Heart failure sarcopenia and adiposity paradoxMitja Lainscak (Slovenia)

4. 12:24 – 12:38Heart Failure Association / European Society of Cardiology position paper on frailty in patients with heart failureCristiana Vitale (Italy)

5. 12:42 – 12:56Adipose tissue browning and vitamin D in chronic illnessRobert Mak (USA)

K 11:30 – 13:00 HALL A

Cachexia, sarcopenia and frailty in acute illness: from mechanisms to therapy


Chairs: Maurilio Sampaolesi (Belgium) Tobias Wollersheim (Germany)

1. 11:30 – 11:42Satellite cells, inflammation and senescenceStephen Harridge (UK)

2. 11:45 – 11:57The inflammatory “genomic storm” post trauma and sepsis – a driver of rapid muscle wastingScott Brakenridge (USA)

3. 12:00 – 12:12Age-related signaling and expression changes that may contribute to sarcopeniaDavid Glass (USA)

4. 12:15 – 12:27Post-sepsis microenvironment alterations in wasting muscle and adipose tissueJason Doles (USA)

5. 12:30 – 12:42Electrical stimulation as an intervention in the critically illSteffen Weber-Carstens (Germany)

6. 12:45 – 12:57Potential nutritional interventions to prevent acute muscle wastingAlessandro Laviano (Italy)

13:15 – 14:15 HALL B

Lunch Seminar

Session on Cachexia Research

Chairs: Bei Zhang (USA) Stefan Anker (Germany)

Introduction: cachexia unmet needs, opportunities and challengesBei Zhang (USA)

Overview of research in cachexiaCancer cachexia focus : HT1080 tumor cachexia model for preclinical researchDanna Breen (USA)

Non-cancer cachexia focus: preclinical models for non-cancer related cachectic and wasting conditionsZhidan Wu (USA)

Wrap up: where do we go from here Stefan Anker (Germany)

In collaboration with Pfizer

mdiek

Durchstreichen

12


L 14:30 – 16:15 HALL B

Late breaking clinical science and clinical trial update


Chairs: Stefan Anker (Germany) Andrew Coats (UK) Marina Zemskova (USA)

1. 14:30 – 14:40The EFFORT study – effective to preserve muscle mass and functional outcomes in critically ill patients Christian Stoppe (Germany)

2. 14:45 – 14:55Endocrine manipulation of cachexia in mice with lung cancerMarcus DaSilva Goncalves (USA)

3. 15:00 – 15:10Beyond ROMANA: moving forward with the anamorelin phase 3 SCALA programRuben Giorgino (Switzerland)

4. 15:15 – 15:25Iodide reduces cachexia in a BALB/c CT26 mouse tumor modelMichael Insko (USA)

5. 15:30 – 15:40Effect of Elamipretide on exercise, muscle strength, and heart function in patients with Barth Syndrome after 48 weeks of therapyJim Carr (USA)

6. 15:45 – 15:55SARA program: preliminary findings from SARA-OBS study and impacts on the SARA-INT study designSamuel Agus (USA)


M 14:30 – 16:00 HALL A

Sarcopenia and aging – diagnosis, exercise, nutrition


Chairs: Vickie Baracos (Canada) Wolfram Doehner (Germany)

1. 14:30 – 14:44The SCWD consensus on sarcopeniaJohn Morley (USA)

2. 14:48 – 15:02Screening for sarcopenia Angela Sanford (USA)

3. 15:06 – 15:20Exercise as a treatment of frailty in hospital careMikel Izquierdo (Spain)

4. 15:24 – 15:38Treating sarcopenia in a rural community Janice Lundy (USA)

5. 15:42 – 15:56Herbal medicine based nutritionAkio Inui (Japan)


13



Poster Viewing 3


Poster session 3 .1 Therapeutic development II (posters 9-11 to 9-17) Chairs: Jose Garcia, Jennifer Le-Rademacher

Poster session 3 .2 Cancer cachexia II (posters 3-13 to 3-23) Chairs: Andrea Bonetto, Paola Costelli

Poster session 3 .3 Diagnosis of sarcopenia III (posters 5-23 to 5-32) Chairs: Mauricio Berriel-Diaz , Ramon Langen

Poster session 3 .4 Muscle wasting & sarcopenia III (posters 6-23 to 6-33) Chairs: Maurilio Sampaolesi, David Waning

Poster session 3 .5 Physical activity & training II (posters 8-12 to 8-22) Chairs: Bette Caan, James Carson

16:10 – 16:50 HALL A



Chairs: Connie Jackaman (Australia) Francesco Landi (Italy)

16:10 – 16:13SRF role as a mechano-transductor in response to exercise in cancer cachexia (3-10)Medhi Hassani (Italy)

16:15 – 16:18Fried frailty phenotype and hand grip strength in advanced cancer patients (6-38)Pia Weinlaender (Germany)

16:20 – 16:23Association of growth differentiation factor 15 and malnutrition inflammation score in a prospective hemodialysis cohort (7-04)Connie Rhee (USA)

16:25 – 16:28Tele-rehabilitation to prevent sarcopenia and disability in advanced cancer: a randomized controlled trial (8-07)Andrea Cheville (USA)

16:30 – 16:33Anaerobic threshold-based exercise training program stimulates genes that control skeletal muscle differentiation and function in heart failure patients (8-10)Renata Dmitrieva (Russia)

16:35 – 16:38Myosin activity triggers muscle growth through a novel mechanotransduction signalling pathway involving Forcin (8-11)Simon Hughes (UK)

16:40 – 16:43Serum Amyloid A1 mediates myotube atrophy via Toll-like receptors (9-07)Melanie Kny (Germany)

16:45 – 16:48Safety and efficacy of bimagrumab in community-dwelling older adults with sarcopenia (9-10)Didier Laurent (USA)

14


N 17:00 – 19:00 HALL B

Hot topic in muscle wasting


Chairs: Jochen Springer (Germany) Xiaonan Wang (USA) Antonio Zorzano (Spain)

1. 17:00 – 17:08Molecular mechanisms and promising therapies in muscle wastingAmanda Vest (USA)

2. 17:12 – 17:20Mytho a novel player in autophagy and cancerMarco Sandri (Italy)

3. 17:24 – 17:32Key facilitator proteins that mediate sarcolemma membrane repair have potential as therapeutics for muscle disease and injuryNoah Weisleder (USA)

4. 17:36 – 17:44Role of the microcirculation in muscle wasting and plasticityHans Degens (UK)

5. 17:48 – 17:56Tissue sodium accumulation and peripheral insulin sensitivity in maintenance hemodialysis patientsTalat Alp Ikizler (USA)

6. 18:00 – 18:08Apelin and sarcopenia of agingCédric Dray (France)

7. 18:12 – 18:20Deacetylase inhibitors to treat muscle wastingVered Raz (The Netherlands)

8. 18:24 – 18:32An update on the role of anabolic steroids in muscle wastingJeffrey Crawford (USA)

18:36 – 19.00Panel discussion

O 17:00 – 19:00 HALL A

The fat and appetite session


Chairs: Stephan Herzig (Germany) Klaske van Norren (The Netherlands)

1. 17:00 – 17:08An update on brown fatJosep Argiles (Spain)

2. 17:12 – 17:20Brown fat and cancer cachexia: understanding interactive mechanismsAnnemie Schols (The Netherlands)

3. 17:24 – 17:32Measuring brown fat in humansJan Nedergaard (Sweden)

4. 17:36 – 17:44TLR4 involvement in adipose tissue loss in cancer cachexia Miguel L. Batista (Brazil)

5. 17:48 – 17:56A novel cancer variant discovered by identifying tumor-driven changes in fat redistributionOliver Bathe (Canada)

6. 18:00 – 18:08The clinical impact and spectrum of obesity and cancerAminah Jatoi (USA)

7. 18:12 – 18:20The gap between existing large population data and the need of novel database relevant to cachexiaMelissa Miller (USA)

8. 18:24 – 18:32In-vivo screening platform to identify new pro-cachectic / anorectic tumor factorsOlivier Bezy (USA)


15

PROGRAM OVERVIEW, SUNDAY, DECEMBER 8, 2019

07:30 – 8:15 HALL II

Ken Fearon Career Café – Meet the Mentor

Coordinated by: Mitja Lainscak (Slovenia)

07:30 – 8:15 HALL A

Statistical Seminar

An introduction to time-to-event (survival) analysis

Coordinated by: Jennifer Le-Rademacher (USA) Ruta Brazauskas (USA)

Time-to-event outcomes such as time from treatment to disease recurrence or time from diagnosis to death are common endpoints in biomedical research. These outcomes require that the study subjects be followed over time. In practice, it is not possible to follow all subjects until they experience the events of interest. The event times for subjects who are lost to follow-up before experiencing the events are not observed. These patients are censored at the time of their last follow-up. Time-to-event analysis (commonly called survival analysis) methods are needed in studies with time-to-event outcome to account for censoring. Due to the complexity of time-to-event methods, knowledge of the method assumptions and basic principles is important. Great care is needed when applying them in practice or interpreting published studies. In this seminar, we will

− Introduce basic concepts of time-to-event data and explain the difference between various types of survival data including competing risks data

− Introduce common analysis methods including the Kaplan-Meier estimator, the Cox proportional hazards model, the cumulative incidence function, and the Fine-Gray model; and

− Provide practical guidance for analyzing time-to-event data.

P 08:30 – 10:00 HALL B

Neurological impact of sarcopenia


Chairs: Akio Inui (Japan) Sein Schmidt (Germany)

1. 08:30 – 08:44Neurophysiological basis of anorexia-cachexia syndrome Toshihiko Yada (Japan)

2. 08:48 – 09:02Sarcopenia in neuromuscular diseasesGabriele Siciliano (Italy)

3. 09:06 – 09:20Stroke and sarcopeniaWolfram Doehner (Germany)

4. 09:24 – 09:38Dementia and sarcopenia . A vicious circle Rainer Wirth (Germany)

5. 09:42 – 09:56Brain wastingMatthias Endres (Germany)

16


Q 8:30 – 10:00 HALL A

Young investigators awards session


Judges: Volker Adams (Germany) Vickie Baracos (Canada) Bette Caan (USA) Paola Costelli (Italy) Steven Heymsfield (USA) Jalid Sehouli (Germany) Florian Strasser (Switzerland)

Basic

8:30 – 8:40Cachexia induced by non-bone metastatic cancers is accompanied by bone, cartilage and bone marrow destruction (2-04)Fabrizio Pin (USA)

8:45 – 8:55Exercise preconditioning diminishes solute carrier protein expression and doxorubicin accumulation in the diaphragm (8-02)Ashley Smuder (USA)

9:00 – 9:10Derangements of amino acids in cachectic skeletal muscle are caused by mitochondrial dysfunction (9-06)Thomas Kunzke (Germany)

Clinical 9:15 – 9:25

Tumor organoids as a novel model to study cancer-induced cachexia in pancreatic cancer (2-08)Rianne Vaes (The Netherlands)

9:30 – 9:40Adverse muscle composition within obesity is associated with low functional performance and increased comorbidity – results from the large UK Biobank imaging study (5-05)Jennifer Linge (Sweden)

9:45 – 9:55Effects of exercise and beta-hydroxy-beta-methylbutyrate supplements on muscle mass, muscle strength, and physical performance in older women with muscle atrophy: a randomized, double-blind, placebo-controlled trial (9-01)Yosuke Osuka (Japan)


17



Poster Viewing 4


Poster session 4 .1 Diagnosis of sarcopenia II (posters 5-13 to 5-22) Chairs: Robert Mak, Angela Sanford

Poster session 4 .2 Diagnosis of sarcopenia IV (posters 5-33 to 5-38) Chairs: Mauricio Berriel-Diaz, Ramon Langen

Poster session 4 .3 Muscle wasting & sarcopenia IV (posters 6-34 to 6-41) Chairs: Maurilio Sampaolesi, David Waning

Poster session 4 .4 Nutrition and appetite I (posters 7-01 to 7-12) Chairs: Olivier Bezy, Klaske van Norren

R 11:00 – 12:30 HALL B

Sex matters in cachexia


Chairs: Yi-Ping Li (USA) Filippo Rossi-Fanelli (Italy)

1. 11:00 – 11:14Multi-platform omics analyses document distinct phenotypes and mechanisms in cancer cachexiaVickie Baracos (Canada)

2. 11:18 – 11:32Sex-specific differences in treatment response in cancer cachexiaJose Garcia (USA)

3. 11:36 – 11:50 Sex specific phenotypes, mechanisms, and treatment response in mice and humans with pancreatic cancerXiaoling Zhong (USA)

4. 11:54 – 12:08Sex differences in imaging for cachexiaSteven Heymsfield (USA)

5 12:12 – 12:26The role of estrogen in cachexia-induced metabolic disruptionsJames Carson (USA)

S 11:00 – 12:30 HALL A

Cancer- and chemotherapy-induced wasting


Chairs: Jeffrey Crawford (USA) Maurizio Muscaritoli (Italy)

1. 11:00 – 11:14Chemotherapy-induced metabolic abnormalities in cancer cachexiaThomas O’Connell (USA)

2. 11:18 – 11:32Skeletal muscle adaptations to chemotherapy and the protective effects of exerciseMichael Toth (USA)

3. 11:36 – 11:50Effects of Activin inhibition on chemotherapy-induced cachexiaJuha Hulmi (Finland)

4. 11:54 – 12:08Chemotherapy to delay / counteract cachexiaFabio Penna (Italy)

5. 12:12 – 12:26Multi-organ contributions to cancer cachexiaStephan Herzig (Germany)

12:30 – 13:00 Lunch break

18


T 13:00 – 13:45 HALL B

Frailty and sarcopenia


Chairs: Jürgen Bauer (Germany) Florian Strasser (Switzerland)

1. 13:00 – 13:12Characterisation of the frail geriatric patient Francesco Landi (Italy)

2. 13:15 – 13:27Exercise to improve muscle health and cancer outcomesBette Caan (USA)

3. 13:30 – 13:42Nutritional interventions: what is the evidence?Mitja Lainscak (Slovenia)

U 13:45 – 15:15 HALL B

Novel ideas to enhance muscle mass and function


Chairs: Maria Carmen Gomez-Cabrera (Spain) Richard Dunne (USA)

1. 13:45 – 13:57Targeting the GDF15/MIC-1 pathway for anorexia / cachexiaSamuel Breit (Australia)

2. 14:00 – 14:12Satellite cells, muscle regeneration, and cancer cachexiaJason Doles (USA)

3. 14:15 – 14:27CD8 T cells – a novel player in cachexia during viral infectionAndreas Bergthaler (Austria)

4. 14:30 – 14:42Making patients fat again: good idea? If so, how?Andrew Coats (UK)

5. 14:45 – 14:57Data-driven identification and optimization of new medicines for cancer cachexiaBen Zeskind (USA)

6. 15:00 – 15:12The HIPGEN Study – Allogeneic cell therapy for muscle injury in phase IIITobias Winkler (Germany)

19


V 15:15 – 16:00 HALL B

Highlights session

Chairs: Stefan Anker (Germany) Mitja Lainscak (Slovenia)

1. 15:15 – 15:25Basic scienceOlivier Bezy (USA)

2. 15:25 – 15:35Clinical science & biomarkersStephan von Haehling (Germany)

3. 15:35 – 15:45Treatment & nutritionAndrew Coats (UK)

Poster AwardsYoung Investigator AwardsFarewell

program overview, friday, december 6, 2019

Documents